Literature DB >> 9695961

Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes.

M Iwanaga1, K Furukawa, T Amenomori, H Mori, H Nakamura, K Fuchigami, S Kamihira, H Nakakuma, M Tomonaga.   

Abstract

Among acquired stem cell disorders, pathological links between myelodysplastic syndromes (MDS) and aplastic anaemia (AA), and paroxysmal nocturnal haemoglobinuria (PNH) and AA, have been often described, whereas the relationship between MDS and PNH is still unclear. We analysed blood cells of patients with MDS to determine the incidence of the PNH clone, and analysed the PIG-A gene to find mutations characteristic of the PNH clone in MDS. In four (10%) of 40 patients with MDS, flow cytometry showed affected erythrocytes and granulocytes negative for decay-accelerating factor (DAF) and CD59. The population of affected erythrocytes was smaller in MDS patients with PNH clone (MDS/PNH) than in patients with de novo PNH, and haemolysis was milder in the MDS/PNH patients. PIG-A mutations were found in granulocytes of all patients with MDS/PNH. In type and site, the PIG-A mutations were heterogeneous, similar to that observed in de novo PNH; i.e. no mutation specific to MDS/PNH was identified. Of note, three of four patients with MDS/PNH each had two PNH clones with different PIG-A mutations, suggesting that PIG-A is mutable in patients with MDS/PNH. In a MDS/PNH patient with trisomy 8, FISH detected a distinct karyotype in a portion of granulocytes with PNH phenotype, indicating that PNH and MDS partly shared affected cells. Thus, MDS predisposes to PNH by creating conditions favourable to the genesis of PNH clone. Considering the increasing prevalence and incidence of MDS, these disorders could be useful for investigating the mechanism by which PIG-A mutation is induced.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9695961     DOI: 10.1046/j.1365-2141.1998.00794.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Pathogenesis of selective expansion of PNH clones.

Authors:  Hideki Nakakuma; Tatsuya Kawaguchi
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

2.  The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS.

Authors:  A M Aalbers; V H J van der Velden; A Yoshimi; A Fischer; P Noellke; C M Zwaan; I Baumann; H B Beverloo; M Dworzak; H Hasle; F Locatelli; B De Moerloose; G Göhring; M Schmugge; J Stary; M Zecca; A W Langerak; J J M van Dongen; R Pieters; C M Niemeyer; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2013-06-28       Impact factor: 11.528

Review 3.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

4.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Mitsuhiro Omine; Taroh Kinoshita; Hideki Nakakuma; Jaroslaw P Maciejewski; Charles J Parker; Gérard Socié
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

5.  Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure.

Authors:  Neal S Young
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

Review 6.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

Review 7.  Management issues in paroxysmal nocturnal hemoglobinuria.

Authors:  Gabrielle Meyers; Charles J Parker
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

8.  Mutation analysis of the PIG-A gene in Korean patients with paroxysmal nocturnal haemoglobinuria.

Authors:  J H Yoon; H I Cho; S S Park; Y H Chang; B K Kim
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

9.  Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.

Authors:  S A Wong; B I Dalal; H A Leitch
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

10.  Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes.

Authors:  Tomoko Hata; Hideki Tsushima; Maki Baba; Yoshitaka Imaizumi; Jun Taguchi; Daisuke Imanishi; Kazuhiro Nagai; Masao Tomonaga; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2013-11-20       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.